- Bupa Platinum consultant
-
Fee assured
-
Awaiting
verification
- Open Referral network
Specialises in
- Colon
- Gynaecology
- Lower GI
Offers
- Face-to-face consultations
- Video and telephone consultations
- Home chemotherapy
About me
Dr Smith specialises in anal, colorectal, ovarian and endometrial cancers. She and has an interest in recruiting into clinical trials in these areas.
She is the Governance and Audit lead for Oncology at CUH and the Clinical Lead for Oncology in Bedford Hospital.
Dr Smith’s specialist training took place in and around London, including UCLH, The Royal Marsden and Mount Vernon Hospitals.
After completing her training she obtained her current Consultant post which is split between Bedford and Addenbrooke's Hospitals.
Her private practice is based in Genesis Care Milton Keynes and Cambridge
Areas of interest
Anal cancer; Ovarian cancer; Endometrial cancer; Colorectal (bowel) cancer; radiotherapy simultaneous integrated boost; SABR, chemo-radiation; chemotherapy; radiotherapy; targeted therapy; endocrine therapy.
Medical secretaries
- Leanne Matthews
- Bedford Hospital Kempston Road BEDFORD MK42 9DJ
- 01234 792023
- 01234 792668
- Leanne.Matthews@bedfordhospital.nhs.uk
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (5-50)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)
GenesisCare, Milton Keynes (5-50)
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (5-50)
-
X6910
Clinical supervision of the planning of a course of simple radiotherapy - (1-5)
-
X0008
Clinical supervision of external beam radiotherapy, for 16 or up to and including 30 fractions - (1-5)
-
X6772
Preparation for complex radiotherapy with Intensity Modulated Radiotherapy (IMRT) - (1-5)
-
X0007
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (1-5)